Abstract: An electromagnetic actuator for non-continuous rotation (cogging-torque actuator (CTA)) (100) comprises a support structure (116), an output shaft (104) rotatable about and defining an axis of rotation (X), a permanent magnet rotor (106) comprising at least two magnetic poles (108a, 108b) attached to the output shaft (104), and a stator device (110) comprising a ferromagnetic pole body (112) attached to the support structure (116) and surrounding the at least two magnetic poles (108a, 108b). The ferromagnetic pole body (112) can have at least four ferromagnetic stator poles (112a-d) each wrapped in a conductive wire (114a-d) to define a stator coil. The at least four ferromagnetic stator poles (112a-d) are sized, and spaced radially from each other, so as to define a maximum cogging torque of the electromagnetic actuator (100). The CTA (100) can operate as an actuator, an elastic spring, a clutch, and/or a load support device.

Abstract: The present invention provides methods of treating myopia comprising administering composition comprising a cop-per-containing agent to an eye of a subject in need thereof.

Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.

Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.

Abstract: Methods and devices for eradicating biofilms and planktonic bacteria are provided. In on embodiment, a therapeutic delivery device comprised of at least a port and a antimicrobial releasing pouch and one or more therapeutic agents is provided to the mammal. In one aspect of at least one embodiment the releasing pouch has an internal reservoir comprised of a membrane that is configured to contain the one or more therapeutic agents that is to be administered to the mammal and the port is in fluid communication with the pouch and configured such that the pouch can be refilled with one or more therapeutic agents via the port. In other aspect of at least one embodiment the method is able to fully eradicate 109 colony forming units (CFU) of methicillin-resistant Staphylococcus aureus (MRSA) within a 24 hr period.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: The disclosure relates to a chondrogenic cell sheet comprising at least two layers of confluent chondrogenically differentiated cells, wherein the cell sheet is prepared from mesenchymal stem cells (MSCs), and wherein the chondrogenically differentiated cells on the basal side of the cell sheet express adhesion molecules. The disclosure also relates to a method of preparing a chondrogenic cell sheet comprising: a) culturing MSCs on temperature responsive cultureware until confluent to form a cell sheet; b) detaching the cell sheet by temperature reduction and allowing the cell sheet to contract, forming a contracted cell sheet; c) contacting the contracted cell sheet with a culture surface; and d) treating the contracted cell sheet on the culture surface with chondrogenic medium and culturing to form a chondrogenic cell sheet. Methods of using the chondrogenic cell sheets to repair cartilage tissue or treat joint disease are also disclosed.

Abstract: A system for harvesting bone material from a bone may include a rotary cutter defining a rotary cutter longitudinal axis extending between a rotary cutter proximal end and a rotary cutter distal end. The rotary cutter may have a drive shaft configured to receive input torque, and an osteochondral cutter configured to cut the tissue and receive the tissue material in response to rotation of the osteochondral cutter under pressure against the tissue. The system may further include a bone port defining a bone port longitudinal axis extending between a bone port proximal end and a bone port distal end. The bone port may have a bone port cannulation sized to closely fit over the osteochondral cutter. At least one of the bone port proximal end and the bone port distal end may be securable to the tissue. A stratiform tissue graft may be delivered through the bone port.

Abstract: A bone screw may be insertable into a bone. The bone screw may have a distal member with bone-engaging threads, a proximal member configured to slidably engage the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member.

Abstract: Technology is described for methods and systems for imaging an object (110). The method can include an image sensor (116) exposed to light (114) from an object (110) without passing the light through an image modification element. Light intensity of the light (114) can be stored as data in a medium. The image data can be analyzed at a processor (902) as a reconstructed image of the object (110).

Abstract: A system for harvesting bone material from a bone may include a rotary cutter defining a rotary cutter longitudinal axis extending between a rotary cutter proximal end and a rotary cutter distal end. The rotary cutter may have a drive shaft configured to receive input torque, and an osteochondral cutter configured to cut the tissue and receive the tissue material in response to rotation of the osteochondral cutter under pressure against the tissue. The system may further include a bone port defining a bone port longitudinal axis extending between a bone port proximal end and a bone port distal end. The bone port may have a bone port cannulation sized to closely fit over the osteochondral cutter. At least one of the bone port proximal end and the bone port distal end may be securable to the tissue. A stratiform tissue graft may be delivered through the bone port.

Abstract: Bioorthogonal molecules are disclosed and described. A bioorthogonal a molecule having a structure according to: where R2, R3, and R4 are independently selected from H, a substituted or unsubstituted C1-C4 alkyl or alkylene group, a substituted or unsubstituted aryl, COOR9, COR9, CONR9R10, CN, CF3, SO2R9, or a tether molecule; R1 is —R5, —OCOR6, —COR7, or —R8; R5 is —R8, —OH, or tosyl; R6 is a nitrophenyl ether or —R8; R7 is —R8; R8 is a payload or a molecular linker to a payload; and R9 and R10 are independently selected from H or a substituted or unsubstituted C1-C4 alkyl or alkene group.

Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

Abstract: Methods, devices, and kits are provided for performing PCR in <20 seconds per cycle, with improved efficiency and yield.

Abstract: Technology is described for methods and systems for a diffractive optic device (525) for holographic projection. The diffractive optic device can include a lens (535) configured to convey a hologram. The lens (535) further comprises a patterned material (510) formed with an array of cells having a non-planar arrangement of cell heights extending from a surface of the patterned material. The lens further optionally comprises a filling material (530) to fill gaps on both surfaces of the patterned material.

Abstract: The disclosure provides a human umbilical cord mesenchymal stem cell sheet comprising one or more layers of confluent human umbilical cord mesenchymal stem cells (hUC-MSCs). The disclosure also provides method for producing hUC-MSC sheets comprising culturing hUC-MSCs in culture solution on a temperature-responsive polymer which has been coated onto a substrate surface of a cell culture support, wherein the temperature-responsive polymer has a lower critical solution temperature in water of 0-80° C.; adjusting the temperature of the culture solution to below the lower critical solution temperature, whereby the substrate surface is made hydrophilic and adhesion of the cell sheet to the surface is weakened; and detaching the cell sheet from the culture support.

Abstract: Disclosed herein, are antibody-polymer-drug conjugates. The conjugate comprises a targeting moiety, one or more polymers, and one or more therapeutic agents. Also described herein, are compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.